RedHill Biopharma ADRs Up; Completes Movantik Acquisition
April 02 2020 - 12:25PM
Dow Jones News
By Michael Dabaie
RedHill Biopharma Ltd. American depositary receipts were up 14%
to $5.23 in late morning trading.
Before the market opened, the biopharmaceutical company focused
on gastrointestinal diseases said it had completed the acquisition
of the global rights, excluding Europe, Canada and Israel, to
Movantik for the treatment of opioid-induced constipation from
AstraZeneca PLC.
The company said it is expanding the promotion of Movantik with
its current sales force of about 100 representatives.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 02, 2020 12:10 ET (16:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
